SCHEMBL2033291

SCHEMBL2033291

C[C@H]1CC[C@@H](C(=O)O)N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2182183 1.00
SCHEMBL1467724 1.00
SCHEMBL1081706 1.00
SCHEMBL6573684 1.00
SCHEMBL3830467 1.00
SCHEMBL26611997 1.00
Hydrochloric Acid SCHEMBL7701941 0.98 CYP2C19 (0.46)
Hydrochloric Acid SCHEMBL7701945 0.98 CYP2C19 (0.46)
Hydrochloric Acid SCHEMBL21874191 0.98 CYP2C19 (0.46)
Hydrochloric Acid SCHEMBL14893315 0.98 CYP2C19 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113480463-A Synthetic method and preparation device of natural amino acid derivative 黄淮学院 2021-10-08 CN claimed
US-20140155371-A1 MULTICOMPONENT CRYSTALLINE SYSTEM OF EZETIMIBE AND PROLINE BASF SE (DE) 2014-06-05 US claimed
WO-2013014604-A1 MULTICOMPONENT CRYSTALLINE SYSTEM OF EZETIMIBE AND PROLINE BASF SE (DE) 2013-01-31 WO claimed
WO-2024044098-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-29 WO disclosed
US-20230339970-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 US disclosed
EP-4214214-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-07-26 EP disclosed
CN-116171280-A Casein kinase 1 delta modulators 詹森药业有限公司 2023-05-26 CN disclosed
WO-2022058920-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 WO disclosed
US-11236046-B2 Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators GENENTECH, INC. (US) 2022-02-01 US disclosed
US-11192875-B2 Processes for preparing antiviral compounds GILEAD PHARMASSET LLC (US) 2021-12-07 US disclosed
US-11149002-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2021-10-19 US disclosed
US-7238724-B2 Antidiabetic agents; hyperlipemic agents; obestity; immunomoderator; atherosclerosis ABBOTT LABORATORIES (US) 2007-07-03 US disclosed
EP-1655372-A2 Production of polyketides and other natural products Biotica Technology Limited (GB) 2006-05-10 EP disclosed
US-20060078980-A1 Production of polyketides and other natural products GREGORY MATTHEW A 2006-04-13 US disclosed
US-20050272132-A1 Production of polyketides and other natural products BIOTICA TECHNOLOGY LIMITED (GB) 2005-12-08 US disclosed
EP-1589031-A2 Production of polyketides and other natural products Biotica Technology Limited (GB) 2005-10-26 EP disclosed
US-20050215784-A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) ABBVIE INC. 2005-09-29 US disclosed
EP-1560811-A2 PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) Abbott Laboratories (US) 2005-08-10 EP disclosed
US-20040121964-A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) ABBOTT LABORATORIES 2004-06-24 US disclosed
WO-2004026822-A2 PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) ABBOTT LABORATORIES (US) 2004-04-01 WO disclosed